Jarushka Naidoo shared a post on X/Twitter:

“Phase II trial of Tumor-Infiltrating Lymphocyte (TIL) therapy (Lifileucel) in Advanced Non-Small Cell Lung Cancer post Immunotherapy with or without chemotherapy:

• Pre-conditioning chemotherapy (Cyclophosphamide/fludara) then TIL, then IL2
• Objective response rate (ORR): 21.4% (6/28)
• In 60% of cases, TIL from lung metastasis 
• 2 treatment related deaths”

Read further.
Source: Jarushka Naidoo/X

Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials. She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.